E
Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
E
Sell
3/8/2023Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 3/8/2023 due to a major decline in the growth index, total return index and valuation index. EBIT declined 296.13% from -$31 to -$122.8, and earnings per share declined from -$0.0003 to -$0.0008.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 3/8/2023 due to a major decline in the growth index, total return index and valuation index. EBIT declined 296.13% from -$31 to -$122.8, and earnings per share declined from -$0.0003 to -$0.0008.
D
Sell
2/13/2023Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 2/13/2023 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.0051 to -$0.0003, and EBIT increased 75.76% from -$127.9 to -$31.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 2/13/2023 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.0051 to -$0.0003, and EBIT increased 75.76% from -$127.9 to -$31.
E
Sell
2/8/2023Downgrade
Actavia Life Sciences, Inc. (RASP) was downgraded to E+ from D- on 02/08/2023.
Actavia Life Sciences, Inc. (RASP) was downgraded to E+ from D- on 02/08/2023.
D
Sell
11/18/2022Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 11/18/2022 due to an increase in the total return index.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 11/18/2022 due to an increase in the total return index.
E
Sell
8/23/2022Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 8/23/2022 due to a substantial decline in the valuation index and growth index. Earnings per share declined from $0.0018 to -$0.0051.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 8/23/2022 due to a substantial decline in the valuation index and growth index. Earnings per share declined from $0.0018 to -$0.0051.
D
Sell
6/17/2022Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 6/17/2022 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 0 to 0.01, and earnings per share increased from -$0.0046 to -$0.004.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 6/17/2022 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 0 to 0.01, and earnings per share increased from -$0.0046 to -$0.004.
E
Sell
6/13/2022Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 6/13/2022 due to a noticeable decline in the growth index, volatility index and total return index.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 6/13/2022 due to a noticeable decline in the growth index, volatility index and total return index.
D
Sell
5/5/2022Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 5/5/2022 due to a substantial increase in the valuation index.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 5/5/2022 due to a substantial increase in the valuation index.
E
Sell
4/20/2022Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.0018 to -$0.0032.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.0018 to -$0.0032.
D
Sell
11/23/2021Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 11/23/2021 due to an increase in the total return index and volatility index.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 11/23/2021 due to an increase in the total return index and volatility index.
E
Sell
11/8/2021Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index.
D
Sell
10/6/2021Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to D- from D on 10/6/2021 due to a noticeable decline in the total return index, volatility index and valuation index.
Rasna Therapeutics, Inc. (RASP) was downgraded to D- from D on 10/6/2021 due to a noticeable decline in the total return index, volatility index and valuation index.
D
Sell
8/20/2021Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D from D- on 8/20/2021 due to a major increase in the growth index and total return index. Earnings per share increased from -$0.0039 to -$0.0018, operating cash flow increased 32.78% from -$121.1 to -$81.4, and EBIT increased 30.98% from -$93.6 to -$64.6.
Rasna Therapeutics, Inc. (RASP) was upgraded to D from D- on 8/20/2021 due to a major increase in the growth index and total return index. Earnings per share increased from -$0.0039 to -$0.0018, operating cash flow increased 32.78% from -$121.1 to -$81.4, and EBIT increased 30.98% from -$93.6 to -$64.6.
D
Sell
3/26/2021Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 3/26/2021 due to an increase in the total return index.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 3/26/2021 due to an increase in the total return index.
E
Sell
1/15/2021Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 1/15/2021 due to a noticeable decline in the growth index. Operating cash flow declined 342.19% from $23.7 to -$57.4, and EBIT declined 43.74% from -$92.6 to -$133.1.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 1/15/2021 due to a noticeable decline in the growth index. Operating cash flow declined 342.19% from $23.7 to -$57.4, and EBIT declined 43.74% from -$92.6 to -$133.1.
D
Sell
10/23/2020Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 10/23/2020 due to an increase in the volatility index and total return index.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 10/23/2020 due to an increase in the volatility index and total return index.
E
Sell
8/21/2020Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 8/21/2020 due to a significant decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.0028 to -$0.04.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 8/21/2020 due to a significant decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.0028 to -$0.04.
D
Sell
7/1/2020Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 7/1/2020 due to a substantial increase in the growth index and volatility index.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 7/1/2020 due to a substantial increase in the growth index and volatility index.
E
Sell
5/20/2020Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 5/20/2020 due to a large decline in the growth index, efficiency index and volatility index.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 5/20/2020 due to a large decline in the growth index, efficiency index and volatility index.
D
Sell
4/14/2020Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 4/14/2020 due to an increase in the volatility index.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 4/14/2020 due to an increase in the volatility index.
E
Sell
3/26/2020Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 3/26/2020 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 0.03 to 0.01, and debt to equity increased from 0.1 to 0.14.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 3/26/2020 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 0.03 to 0.01, and debt to equity increased from 0.1 to 0.14.
D
Sell
4/4/2019Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 4/4/2019 due to an increase in the valuation index.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E+ on 4/4/2019 due to an increase in the valuation index.
E
Sell
10/3/2018Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 10/3/2018 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.38 to 0.07.
Rasna Therapeutics, Inc. (RASP) was downgraded to E+ from D- on 10/3/2018 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.38 to 0.07.
D
Sell
7/5/2017Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E on 7/5/2017 due to a noticeable increase in the total return index and solvency index. The quick ratio increased from 1.18 to 2.71.
Rasna Therapeutics, Inc. (RASP) was upgraded to D- from E on 7/5/2017 due to a noticeable increase in the total return index and solvency index. The quick ratio increased from 1.18 to 2.71.
E
Sell
4/18/2017Downgrade
Rasna Therapeutics, Inc. (RASP) was downgraded to E from E+ on 4/18/2017 due to a noticeable decline in the volatility index and total return index.
Rasna Therapeutics, Inc. (RASP) was downgraded to E from E+ on 4/18/2017 due to a noticeable decline in the volatility index and total return index.
E
Sell
4/3/2017Upgraded
Rasna Therapeutics, Inc. (RASP) was upgraded to E+ from E on 4/3/2017 due to an increase in the growth index and valuation index.
Rasna Therapeutics, Inc. (RASP) was upgraded to E+ from E on 4/3/2017 due to an increase in the growth index and valuation index.
E
Sell
3/16/2017None
Actavia Life Sciences, Inc. (RASP) was downgraded to E from U on 03/16/2017.
Actavia Life Sciences, Inc. (RASP) was downgraded to E from U on 03/16/2017.
OTC PK
07/22/2024 10:44AM Eastern
Quotes delayed
